# 7 States That Could Still Legalize Cannabis in 2026 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/7-states-cannabis-legalization-2026/ > **Published:** 2026-03-20T17:48:40-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:14:51-04:00 > **Clinical Summary:** Explore the 7 states cannabis legalization 2026 landscape and its clinical impact. Understand medical cannabis research programs and policy updates. --- ✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyResearchMedical Cannabis Why This Matters Clinicians in North Carolina should monitor potential medical [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) because it could expand treatment options for patients with conditions where conventional therapies have failed or caused significant side effects. A legalized research program framework would generate clinical data on cannabis efficacy and safety in specific patient populations, allowing evidence-based prescribing practices to replace current reliance on anecdotal information. Understanding the timeline and structure of potential legalization helps clinicians prepare to counsel patients about cannabis as an adjunctive therapy and recognize when they can legally participate in or refer patients to registered research studies. Clinical Summary This article examines potential [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) developments across seven states in 2026, with particular focus on North Carolina’s proposed [medical cannabis research](https://cedclinic.com/cannabis-varieties-differentiation-cannabinomics/) program that would allow eligible patients to participate in registered clinical studies. For clinicians, such state-level policy shifts are clinically relevant because they determine whether cannabis becomes a legal treatment option within their jurisdiction and what regulatory framework governs its use. North Carolina’s research-focused approach suggests a pathway to medical legalization that prioritizes evidence generation while maintaining clinical oversight through registered study protocols. If these states move toward legalization, physicians will need to understand new prescribing regulations, product standards, and clinical guidelines that emerge alongside policy changes. The variation in legalization models across states underscores the fragmented landscape clinicians currently navigate, where federal prohibition conflicts with state-level authorization. Clinicians should monitor their state’s legalization timeline to prepare for potential shifts in how they counsel patients about cannabis as a therapeutic option and what evidence-based guidelines will apply. Dr. Caplan’s Take “What we’re seeing in states like North Carolina is the recognition that research access pathways, while limited, create an opportunity to gather real-world evidence on cannabis efficacy for specific conditions, and that data will ultimately drive better clinical decision-making than ideology in either direction.” Clinical Perspective As additional states move toward medical cannabis legalization, clinicians should recognize that the regulatory and research frameworks governing access will likely remain heterogeneous, complicating evidence generation and clinical guidance. North Carolina’s potential research program model, which would restrict access to registered study participants, may actually advance evidence quality by creating controlled conditions to evaluate efficacy and safety in specific patient populations, though this approach simultaneously limits patient access and may not reflect real-world prescribing contexts. The fragmented state-by-state legalization landscape means that clinicians cannot rely on a unified national standard for counseling patients, managing drug interactions, or understanding product quality and labeling requirements. Practitioners should stay informed about their own state’s regulatory trajectory while maintaining realistic expectations about the evidence base for cannabis, recognizing that research programs may eventually provide higher-quality data but that many clinical decisions today rest on incomplete information. A practical approach is to document cannabis use discussions and remain open to revising 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+7+States+That+Could+Still+Legalize+Cannabis+in+2026+%40drcaplan&url=https%3A%2F%2Fwww.cannabisbusinesstimes.com%2Flegislation-and-regulation%2Fadult-use-legalization-bill%2Fnews%2F15820227%2F7-states-that-could-still-legalize-cannabis-in-2026)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.cannabisbusinesstimes.com%2Flegislation-and-regulation%2Fadult-use-legalization-bill%2Fnews%2F15820227%2F7-states-that-could-still-legalize-cannabis-in-2026)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+7+States+That+Could+Still+Legalize+Cannabis+in+2026+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.cannabisbusinesstimes.com%2Flegislation-and-regulation%2Fadult-use-legalization-bill%2Fnews%2F15820227%2F7-states-that-could-still-legalize-cannabis-in-2026)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - First-of-its-kind long-term study at Virginia Tech shares how cannabis use can affect driving - [CED Digest: 230 Items — March 18, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 239 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-digest-march-17-2026/) 📰 Source: [https://www.cannabisbusinesstimes.com/legislation-and-regulation/adult-use-legalization-bill/news/15820227/7-states-that-could-still-legalize-cannabis-in-2026](https://www.cannabisbusinesstimes.com/legislation-and-regulation/adult-use-legalization-bill/news/15820227/7-states-that-could-still-legalize-cannabis-in-2026) Further Reading CED Clinic Blog[Alabama Medical Cannabis Commission audit finds violations, $200K overpayment – WBRC](https://cedclinic.com/alabama-medical-cannabis-commission-audit-violations/) Evidence Watch[Comprehensive Review Reveals Cannabis Use Disorder Affects 10% of World’s 193 Million Cannabis Users](https://cedclinic.com/cannabis-use-disorder-epidemiology-global-review/) Cannabis Policy Wire[Policy Watch: 10 Regulatory Updates — March 20, 2026](https://cedclinic.com/dea-rescheduled-marijuana-regulatory-update-march-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence Congress wants federal study of state cannabis laws (Newsletter: April 21, 2026) – Marijuana Moment Learn about federal initiatives to study state cannabis laws and their implications for legalization and research. Read More [Missouri regulators propose rules to set up marijuana research facilities](https://cedclinic.com/missouri-cannabis-research-facilities-proposed-rules/) Explore Missouri's regulatory efforts to establish marijuana research facilities supporting clinical studies. [Explore Details](https://cedclinic.com/missouri-cannabis-research-facilities-proposed-rules/) [Drug Development, Tax Breaks, Future Reimbursement Expected After Medical Marijuana …](https://cedclinic.com/cannabis-drug-development-tax-incentives-clinical-impact/) Understand how medical marijuana legalization drives [drug development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/), tax incentives, and clinical reimbursement. [Learn More](https://cedclinic.com/cannabis-drug-development-tax-incentives-clinical-impact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).